Retatrutide
GZBF
Eli Lilly · Phase 2 · Recruiting · Enrollment 300
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Retatrutide (LY3437943) 1 mg once weekly (no escalation) | Obesity or overweight | 1 mg | n/r | n/r | n/r |
| Retatrutide 4 mg once weekly, escalation subgroup (a): 2 mg → 4 mg. | Obesity or overweight | 4 mg | n/r | n/r | n/r |
| Retatrutide 4 mg once weekly, subgroup (b): start 4 mg (no escalation). | Obesity or overweight | 4 mg | n/r | n/r | n/r |
| Retatrutide 8 mg once weekly, subgroup (a): 2 mg → 4 mg → 8 mg | Obesity or overweight | 8 mg | n/r | n/r | n/r |
| Retatrutide 12 mg once weekly: 2 mg → 4 mg → 8 mg → 12 mg. | Obesity or overweight | 12 mg | n/r | n/r | n/r |
| Placebo once weekly (matched escalation schedule to maintain blinding). | Obesity or overweight | n/r | n/r | n/r | n/r |
| Retatrutide 8 mg once weekly, subgroup (b): 4 mg → 8 mg. | Obesity or overweight | 8 mg | n/r | n/r | n/r |